Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 7c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Eagle Pharmaceuticals (EGRX) PT Lowered to $64 at RBC Capital
November 2, 2018 7:01 AM EDTRBC Capital analyst Randall Stanicky lowered the price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $64.00 (from $84.00) while maintaining an Outperform rating.
Stanicky said results place a spotlight on recent pipeline setbacks and outlook.
... MorePiper Jaffray Downgrades Eagle Pharmaceuticals (EGRX) to Neutral
October 31, 2018 3:11 AM EDTPiper Jaffray analyst David Amsellem downgraded Eagle Pharmaceuticals (NASDAQ: EGRX) from Overweight to Neutral with a price target of $54.00 (from $82.00).
For an analyst ratings summary and ratings history on Eagle Pharmaceuticals click here. For more ratings news on Eagle Pharmaceuticals click here.
Shares of Eagle Pharmaceuticals closed at $47.50 yesterday.
... MoreEagle Pharmaceuticals (EGRX) Reports Prelim. 3Q EPS Above Consenus, Prelim. 3Q Revenues Below Consensus
October 30, 2018 7:34 AM EDTEagle Pharmaceuticals, Inc. (NASDAQ: EGRX) today provided preliminary financial results and announced that its Board of Directors has approved a new stock repurchase program providing for the repurchase of up to an aggregate of $150 million of Eagles common stock, consisting of (i) up to $50 million in repurchases pursuant to an accelerated... More
Eagle Pharmaceuticals (EGRX) Initiates $50M Accelerated Share Buyback as Part of New $150M Share Buyback Authorization
October 30, 2018 7:31 AM EDTEagle Pharmaceuticals, Inc. (NASDAQ: EGRX) today provided preliminary financial results and announced that its Board of Directors has approved a new stock repurchase program providing for the repurchase of up to an aggregate of $150 million of Eagles common stock, consisting of (i) up to $50 million in repurchases pursuant to an accelerated share repurchase (ASR) transaction with JPMorgan Chase Bank, National Association (JP Morgan) and (ii) up to $100 million in additional repurchases. This reflects the Company's conviction in its business strategy.
The specific... More
